Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials
Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc.
Arvinas Inc. (ARVN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 3,689,201 | $43,753,924 | +11% | 0.02% |
| 2. | Point72 Asset Management Steve Cohen | 2,315,361 | $27,460,181 | 0.03% | |
| 3. | Armistice Capital Steven Boyd | 1,800,000 | $21,348,000 | +50% | 0.25% |
| 4. | Millennium Management Israel Englander | 1,259,441 | $14,936,970 | -41% | 0.01% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 619,900 | $7,352,014 | +4706% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.40 | 20,000 | $268,070.00 | 96,021 | 2026-03-06 | Filing | |
| $7.57 | 30,000 | $227,010.00 | 76,021 | 2025-09-22 | Filing | |
| $70.00 | 142,857 | $9,999,990.00 | 822,857 | 2020-12-18 | Filing | |
| $23.99 | 8,333 | $199,908.67 | 42,718 | 2020-11-09 | Filing | |
| $30.26 | 2,000 | $60,519.80 | 79,546 | 2020-06-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.10 | 6,435 | $71,431.07 | 202,503 | 2026-03-18 | Filing | |
| $13.14 | 11,787 | $154,881.18 | 1,122,183 | 2026-02-27 | Filing | |
| $13.24 | 18,822 | $249,203.28 | 1,133,970 | 2026-02-27 | Filing | |
| $13.24 | 4,688 | $62,069.12 | 1,152,792 | 2026-02-27 | Filing | |
| $12.16 | 1,108 | $13,473.28 | 29,692 | 2026-02-23 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,889,628 | $41,230,057 | 0% | |
| 2. | 2,689,362 | $28,507,237 | 0% | |
| 3. | 485,764 | $5,147,064 | 0% | |
| 4. | 412,596 | $4,373,518 | 0% | |
| 5. | 406,340 | $4,307,204 | 0% |
News See All
11 Best Cancer Stocks to Invest In Now
Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
Arvinas, Inc. (NASDAQ:ARVN) Q4 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Arvinas fourth quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise.
Arvinas, Inc. (NASDAQ:ARVN) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Arvinas Third Quarter 2025 Earnings Call. I'd like to remind everyone that this call is being recorded. [Operator Instructions] Thank you.
Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco
Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in Arvinas, Inc.
8 Best US Stocks Under $10 to Invest in
Everyone seeks a stock that has good upside potential, but a stock that is cheap and has good prospects - that’s what a steal deal looks like.
Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment
Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in collaboration with Pfizer Inc.
9 Best Small Cap Stocks with Biggest Upside Potential
On August 14, Jonathan Krinsky of BTIG, joined 'Closing Bell' on CNBC to discuss whether the recent rally in small cap stocks is sustainable.
Arvinas, Inc. (NASDAQ:ARVN) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I would like to welcome everyone to Arvinas' Second Quarter 2025 Earnings Call.
Arvinas, Inc. (ARVN): A Bull Case Theory
This stock is one of several featured in our latest research.
Hedge Fund Resource Center